Keio University Health Center, Yokohama, Japan.
Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Ren Fail. 2023 Dec;45(1):2169618. doi: 10.1080/0886022X.2023.2169618.
BACKGROUND: Pre-emptive kidney transplantation (PEKT), i.e., transplantation performed before initiation of maintenance dialysis, is considered an ideal renal replacement therapy because there is no exposure to long-term dialysis therapy. Therefore, we summarized advantages/disadvantages of PEKT to assist in deciding whether kidney transplantation should be performed pre-emptively. METHODS: This study was registered with PROSPERO, CRD42021269163. Observational studies comparing clinical outcomes between PEKT and non-PEKT were included; those involving only pediatric recipients or simultaneous multi-organ transplantations were excluded. The PubMed/MEDLINE, Cochrane Library, and Ichushi-Web databases were searched on 1 August 2021. Studies were pooled using the generic inverse-variance method with random effects model, and risk of bias was assessed using ROBINS-I. RESULTS: Seventy-six studies were included in the systematic review (sample size, 23-121,853; enrollment year, 1968-2019). PEKT patients had lower all-cause mortality (adjusted HR: 0.78 [95% CI 0.66-0.92]), and lower death-censored graft failure (0.81 [0.67-0.98]). Unadjusted RRs for the following outcomes were comparable between the two patient groups: cardiovascular disease, 0.90 (0.58-1.40); biopsy-proven acute rejection, 0.75 (0.55-1.03); cytomegalovirus infection, 1.04 (0.85-1.29); and urinary tract infection, 0.89 (0.61-1.29). Mean differences in post-transplant QOL score were comparable in both groups. The certainty of evidence for mortality and graft failure was moderate and that for other outcomes was very low following the GRADE classification. CONCLUSIONS: The present meta-analysis shows the potential benefits of PEKT, especially regarding patient and graft survival, and therefore PEKT is recommended for adults with end-stage kidney disease.
背景:预防性肾移植(PEKT)即在开始维持性透析前进行的移植,被认为是一种理想的肾脏替代治疗方法,因为患者无需接受长期透析治疗。因此,我们总结了 PEKT 的优缺点,以帮助决定是否应进行预防性肾移植。
方法:本研究已在 PROSPERO 上注册,注册号为 CRD42021269163。纳入了比较 PEKT 和非 PEKT 患者临床结局的观察性研究;排除了仅涉及儿科受者或同时进行多器官移植的研究。于 2021 年 8 月 1 日检索了 PubMed/MEDLINE、Cochrane 图书馆和 Ichushi-Web 数据库。使用随机效应模型的通用倒数方差法对研究进行汇总,并使用 ROBINS-I 评估偏倚风险。
结果:系统评价纳入了 76 项研究(样本量 23-121853,入组年份 1968-2019)。PEKT 患者的全因死亡率较低(校正 HR:0.78[95%CI 0.66-0.92]),且死亡相关移植物失功率较低(0.81[0.67-0.98])。两组患者的以下结局的未经校正 RR 相似:心血管疾病,0.90(0.58-1.40);经活检证实的急性排斥反应,0.75(0.55-1.03);巨细胞病毒感染,1.04(0.85-1.29);和尿路感染,0.89(0.61-1.29)。两组患者的移植后 QOL 评分的均值差异无统计学意义。根据 GRADE 分类,死亡率和移植物失功率的证据质量为中等,其他结局的证据质量极低。
结论:本荟萃分析表明,PEKT 具有潜在的益处,尤其是在患者和移植物存活率方面,因此建议对终末期肾病的成人患者进行 PEKT。
Medicine (Baltimore). 2024-6-21
Nephrol Dial Transplant. 2019-4-1
Cochrane Database Syst Rev. 2022-2-1
Pediatr Int. 2019-6
Ont Health Technol Assess Ser. 2010
Health Technol Assess. 2016-8
Nefrologia (Engl Ed). 2020
Nephrol Ther. 2013-9
Clin Kidney J. 2025-5-13
World J Transplant. 2025-3-18
Clin J Am Soc Nephrol. 2025-4-1
Clin Kidney J. 2024-12-9
Am J Transplant. 2025-4
Clin J Am Soc Nephrol. 2019-8-27
J Am Soc Nephrol. 2019-7-15
Clin J Am Soc Nephrol. 2018-8-7